-
| Sector | Healthcare |
|---|---|
| Industry | Biotechnology |
| ISIN | US52635N1037 |
| Exchange | NASDAQ |
| CurrencyCode | USD |
| PE Ratio | None |
|---|---|
| Target Price | 44.625 |
| Beta | nan |
| Market Cap | 742M |
| Dividend Yield | None |
LENZ Therapeutics, Inc. operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for LENZ using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025